Folate receptor alpha detection kit for accompanying diagnosis of ovarian cancer patients

The folic acid receptor α detection kit detects the FRα expression in ovarian cancer patients. Combined with the TPS scoring standard, the problem of poor treatment effect caused by insufficient FRα expression in the prior art is solved, and an individualized treatment plan for ovarian cancer patients is realized Selection improves treatment effect and patient quality of life.

CN118914552AInactive Publication Date: 2024-11-08KAQIU (JIANGSU) BIOTECHNOLOGY CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410826951.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-19
Filing Date
2024-06-25
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art lacks concomitant diagnostic methods for FRα expression in patients with ovarian cancer, resulting in poor therapeutic effects of ADC drugs targeting FRα, especially when FRα is insufficient, it is difficult for patients to obtain effective treatment.

Method used

Provide a folate receptor α detection kit for ovarian cancer patients. The FRα expression in samples is detected by immunohistochemistry, and the patients are divided into two categories: FRα positive and negative, and the Tumor Proportion Score (TPS) score is used. Standard assisted clinicians to screen appropriate treatment options.

Benefits of technology

It improves the therapeutic effect of ADC drugs, avoids ineffective treatment for FRα-negative patients, increases the drug choice for FRα-positive patients, provides individualized treatment plans for ovarian cancer patients, and improves quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118914552A_ABST
    Figure CN118914552A_ABST
Patent Text Reader

Abstract

The invention discloses a folate receptor alpha detection kit for accompanying diagnosis of ovarian cancer patients, the folate receptor alpha detection kit comprises a negative quality control product and a positive quality control product, the negative quality control product is a paraformaldehyde solution containing FRalpha negative cells, the positive quality control product is a paraformaldehyde solution containing FRalpha positive cells, the FRalpha negative cells are human embryo kidney cells HEK293, and the negative quality control product is a folate receptor alpha detection product. FRalpha positive cells are human cervical cancer cells Hela. The detection kit is used for detecting a sample, ovarian cancer patients can be divided into FRalpha positive and FRalpha negative types, clinical doctors are assisted in screening ovarian cancer patients which can be treated by using an ADC drug targeting FRalpha, the patients with FRalpha negative expression are prevented from receiving invalid treatment, and the drug selection of the ovarian cancer patients with FRalpha positive is increased.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of tumor detection, and in particular relates to a folate receptor alpha detection kit for concomitant diagnosis of ovarian cancer patients. Background Art

[0002] Anti-body Drug Conjugates (ADCs) are a class of targeted biological agents composed of antibodies, linkers, and cytotoxic drugs, and have attracted much attention in the field of cancer treatment drug development. This is because the monoclonal antibodies on ADC drugs can target antigens specifically expressed on cancer cells based on the antigen-antibody binding mechanism, bringing the drugs to the vicinity of cancer cells or inside the cancer cells for release, effectively avoiding the side effects of traditional chemical drugs and significantly increasing the effectiveness of drug treatment.

[0003] The incidence of ovarian cancer is second only to cervical cancer and endometrial cancer among gynecological malignancies. In addition, due to the lack of effective treatment, the mortality rate of ovarian cancer patients exceeds the sum of cervical cancer and endometrial cancer, ranking first among gynecological cancers. Therefore, it is also called the "king of gynecological cancers." Statistics show that the 5-year survival rate of ovarian cancer patients is only 30%. In particular, the treatment efficiency of platinum-resistant recurrent ovarian cancer is low, and the expected total survival time is often less than 1 year. There is an urgent need to develop more effective therapeutic drugs.

[0004] Folate receptor α is a glycoprotein distributed on the surface of the cell membrane. It can trigger the endocytosis of the cell membrane to mediate the entry of ligands into the cell and participate in regulating the infiltration, proliferation and metastasis of tumor cells. Many clinical studies have pointed out that FRα is expressed in nearly 90% of advanced ovarian cancer tissues, while FRα expression is almost negligible in non-malignant tissues. Therefore, FRα is an ideal target for the development of anti-ovarian cancer ADC drugs, and many drugs are currently undergoing clinical trials around the world. For example, the sometuximab injection developed by Sino-US Huadong and its US partner ImmunoGen, Inc. was approved by the National Medical Products Administration (NMPA) in April 2024 to conduct relevant clinical trials. In fact, the drug was fully approved by the FDA in November 2022 for the treatment of adult patients with FRα-positive platinum-resistant recurrent ovarian cancer who have previously received 1 to 3 systemic treatments.

[0005] According to the treatment principle of ADC drugs, relevant effects can only be exerted when specific antigens are expressed in the patient's body. Taking the ADC drug targeting FRα for the treatment of ovarian cancer patients as an example, if the ovarian cancer cells in the patient's body do not express FRα, or the expression level is very low, it is difficult to benefit from ADC drug treatment. Therefore, before administering ADC drugs, it is necessary to detect the expression status of specific antigens in the patient's body, that is, companion diagnosis, to avoid ineffective medication for patients.

[0006] Immunohistochemistry is a classic technique for detecting the expression of specific antigens in tumor cells. The ADC drug targeting Her-2 protein that has been approved for marketing uses this method to detect the expression of Her-2 protein in tumor tissues of breast cancer patients. However, in the field of ADC drug development targeting FRα for the treatment of ovarian cancer patients, there is no FRα detection kit for companion diagnosis on the market. Summary of the invention

[0007] In order to address the deficiencies of the prior art, the purpose of the present invention is to provide a folate receptor alpha detection kit for companion diagnosis of ovarian cancer patients. By using the detection kit to detect samples, ovarian cancer patients can be divided into two categories: FRα-positive and FRα-negative, assisting clinicians in screening ovarian cancer patients who can be treated with ADC drugs targeting FRα, avoiding ineffective treatment for patients with FRα-negative expression, and increasing the drug options for FRα-positive ovarian cancer patients.

[0008] In order to achieve the above object, the present invention adopts the following technical solution: A folate receptor alpha detection kit for companion diagnosis of ovarian cancer patients comprises: a negative quality control and a positive quality control, the negative quality control is a paraformaldehyde solution containing FRα-negative cells, the positive quality control is a paraformaldehyde solution containing FRα-positive cells, the FRα-negative cells are human embryonic kidney cells HEK293, and the FRα-positive cells are human cervical cancer cells Hela.

[0009] Preferably, the concentration of HEK293 cells in the negative control and the concentration of Hela cells in the positive control are both 1×10 4 cells / mL.

[0010] Preferably, the paraformaldehyde solution comprises the following components in percentage by weight: 3% to 5% paraformaldehyde, 0.1% to 0.5% pH stabilizer, and the balance is water.

[0011] Preferably, the pH stabilizer comprises disodium hydrogen phosphate and potassium dihydrogen phosphate in a mass ratio of 5-10:1.

[0012] Preferably, the method of using the kit is as follows: S1. Sample preparation: Cryosection the neutral formalin-fixed and paraffin-embedded ovarian cancer tissue samples, fix them on glass slides, drop negative and positive quality control samples near the ovarian cancer tissue sections, and place the samples in an oven to dry; S2. Sample testing: Use the detection kit to perform immunohistochemical staining on the prepared samples above and observe the staining results.

[0013] Preferably, in step S1, the thickness of the ovarian cancer tissue sample slice is 4-5 μm, and the amount of negative quality control cells and positive quality control cells is 5-10 μL.

[0014] Preferably, when the staining result of the negative quality control cell HEK293 is negative, and the staining result of the positive quality control cell Hela is positive, the staining result of the ovarian cancer tissue section sample is interpreted, and the specific interpretation method is as follows: (1) When tumor cells show incomplete membrane positive staining or no positive staining, the staining intensity is 0; (2) When tumor cells show incomplete membrane-positive staining and can only be observed under a 40x microscope, the staining intensity is 1+; (3) When the tumor cells show partially intact membrane positive staining and can be observed under a 10x microscope, the staining intensity is 2+; (4) When tumor cells show complete membrane positive staining and can be observed under a 4x microscope, the staining intensity is 3+.

[0015] Preferably, the ratio of tumor cells with staining intensity 2+ and 3+ to all live tumor cells with staining intensity 0, 1+, 2+, and 3+, i.e., the Tumor Proportion Score (TPS), is calculated according to the following formula:

[0016] Preferably, the sample staining result interpretation criteria are: (1) If TPS is less than 50%, it is interpreted as negative, and the ovarian cancer patient is not suitable for ADC drug treatment targeting FRα; (2) If TPS ≥ 75%, it is interpreted as positive, and the ovarian cancer patient can benefit significantly from ADC drug treatment targeting FRα; (3) If 50%≤TPS<75%, it is not recommended for the ovarian cancer patient to receive ADC drug treatment targeting FRα.

[0017] The detection kit is used to assist clinicians in screening ovarian cancer patients who can be treated with ADC drugs targeting FRα.

[0018] The present invention is beneficial in that: (1) The present invention is used for companion diagnosis of ovarian cancer patients. Through immunohistochemical detection technology, ovarian cancer patients are divided into two categories: FRα-positive and FRα-negative. A set of TPS scoring standards for FRα expression is established to evaluate the relative content of FRα-expressing tumor cells in all tumor cells, which can provide assistance for the development of ADC drugs targeting FRα. (2) The present invention also provides negative and positive cell quality control products, which can monitor the entire process of immunohistochemical staining from tissue section samples, improve the accuracy of test results, and avoid false negative results being accepted; (3) The present invention can divide ovarian cancer patients into two categories: FRα-positive and FRα-negative, assisting clinicians in screening ovarian cancer patients who can be treated with ADC drugs targeting FRα, avoiding ineffective treatment for patients with FRα-negative expression, increasing the drug options for FRα-positive ovarian cancer patients, providing clinicians with more personalized treatment plans, and improving the quality of life of ovarian cancer patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 The figures are staining effect diagrams of the kit of the present invention and the imported kit of the same type (AD are staining effect diagrams of the VENTANA folate receptor α detection reagent developed by the imported Roche Diagnostics Company on ovarian cancer tissue section samples with high, medium, low and no expression of FRα; EH are staining effect diagrams of the folate receptor α detection reagent of the present invention on ovarian cancer tissue section samples with high, medium, low and no expression of FRα); Figure 2 The figure shows the screening results of negative quality control cells and positive quality control cells in the kit of the present invention (A: human embryonic kidney cells HEK293, B: human peripheral blood mononuclear cells PBMC, C: human T lymphoid leukemia cells Jurkat, D: human prostate cancer cells PC-3, E: human cervical cancer cells Hela, F: human breast cancer cells MCF-7, G: human liver cancer cells HepG2, H: human ovarian cancer cells A2780). DETAILED DESCRIPTION

[0020] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.

[0021] Example 1, optimal staining procedure of folate receptor α detection kit: The present invention explores a set of staining procedures that are most suitable for the folate receptor α detection kit of the present invention by gradually adjusting the dewaxing temperature, dewaxing time, antigen retrieval temperature, antigen retrieval time, incubation time of rabbit anti-FRα antibody and incubation time of secondary antibody polymer in the immunohistochemical staining process. Compared with the same type of folate receptor α detection kit, the positive intensity is higher and the staining background is lower.

[0022] The test results of the optimal dewaxing temperature, dewaxing time, antigen retrieval temperature, antigen retrieval time, incubation time of rabbit anti-FRα antibody and incubation time of secondary antibody polymer are shown in Table 1.

[0023] Table 1 Staining procedure test of folate receptor α detection kit

[0024] The parameters that most affect the staining results are mainly the antigen repair process. When the antigen repair temperature or time is insufficient, the TPS score of the staining result will be significantly reduced, especially for ovarian cancer tissue samples with low expression of FRα. Therefore, the present invention selects 101°C repair for 11 min, repeated 3 times, to fully ensure that the antigen repair process is correct. Similarly, the present invention selects 72°C dewaxing for 3 min, repeated 4 times; 37°C rabbit anti-FRα antibody incubation for 33 min; 37°C secondary antibody polymer incubation for 25 min.

[0025] Therefore, the optimal staining procedure of the folate receptor α detection kit of the present invention is shown in Table 2.

[0026] Table 2. Optimal staining procedure for the folate receptor α detection kit of the present invention

[0027] Example 2: Comparison of staining effects of folate receptor α detection kits The VENTANA folate receptor α detection reagent developed by Roche Diagnostics is currently the only FDA-approved companion diagnostic reagent for the innovative drug ELAHERE for the treatment of platinum-resistant recurrent ovarian cancer (PROC) in the world. The present invention compared the staining effect of the kit with that of the imported Roche Diagnostics kit of the same type on 4 ovarian cancer tissue samples with high, medium, low, and no FRα expression. The results are as follows: Figure 1 shown.

[0028] according to Figure 1 It can be seen that the staining effect of the present invention on ovarian cancer tissue samples with high, medium and no expression of FRα ( Figure 1 E, F and H) and the staining effect of the imported kit ( Figure 1 -A, B and D), no significant difference was found, but in samples with low FRα expression, the staining effect of the present invention ( Figure 1 -G) than the imported kit ( Figure 1 -C) is clearer, with higher staining intensity, lower staining background, and more obvious contrast.

[0029] Example 3, Screening of FRα negative quality control cells and positive quality control cells: The present invention collected 4 cell lines with high and low expression of FRα, namely human embryonic kidney cells HEK293, human peripheral blood mononuclear cells PBMC, human T lymphocyte leukemia cells Jurkat, human prostate cancer cells PC-3, human cervical cancer cells Hela, human breast cancer cells MCF-7, human liver cancer cells HepG2, and human ovarian cancer cells A2780. According to the sample preparation method of the present invention, the above cells were prepared into cell quality control samples on a glass slide. Then, the optimal staining procedure for FRα explored in Example 1 was used for detection, and the results were as follows. Figure 2 shown.

[0030] according to Figure 2 It can be seen that among the four different types of FRα low-expressing cell lines, HEK293 cells ( Figure 2 -A) and PBMC cells ( Figure 2 -B) No FRα staining was detected, while Jurkat cells ( Figure 2 -C) and PC-3 cells ( Figure 2 -D) Low level of FRα staining was detected. Among the four different types of FRα high-expressing cell lines, Hela cells ( Figure 2 -E) and MCF-7 cells ( Figure 2 -F) detected clear and complete cell membrane staining, while HepG2 cells ( Figure 2 -G) and A2780 cells ( Figure 2 -H) Not only cell membrane staining was detected, but also obvious staining was detected in the cytoplasm and nucleus, which may be due to the excessive expression level of FRα. Considering the growth rate of the cells themselves and their purchase price and other factors, the present invention finally selected HEK293 cells and Hela cells as the negative and positive quality control cells of the folate receptor α detection kit, respectively.

[0031] Example 4: Detection of folate receptor α detection kit in ovarian cancer patients: In order to evaluate the detection rate of the folate receptor α detection kit in ovarian cancer patients, the present invention included 106 ovarian cancer patients with different pathological types in a clinical study for detection, and the results are shown in Tables 3 and 4.

[0032] Table 3. Overall expression of FRα in ovarian cancer samples

[0033] Table 4. FRα expression in different ovarian cancer types

[0034] According to Tables 3 and 4, the number of samples with TPS values ​​of FRα in the intervals of [0, 25%), [25%, 50%), [50%, 75%) and [75%, 100%) of ovarian cancer patients accounted for 26.42%, 7.55%, 18.87% and 47.12% of all samples, respectively. That is, the folate receptor α detection kit of the present invention detected high expression of FRα in nearly half of ovarian cancer patients.

[0035] Among them, high-grade serous carcinoma is the most common pathological type in patients with advanced ovarian cancer, accounting for nearly 70%. In high-grade serous carcinoma, the detection rate of FRα is very high, reaching 90.14% (TPS≥25%) and 97.18% (TPS≥1%).

[0036] In low-grade serous carcinoma, the detection rate of FRα is as high as 80% (TPS ≥ 25%) and 100% (TPS ≥ 1%), but low-grade serous carcinoma is not common in patients with advanced ovarian cancer, with a level of only about 5%. In addition, although the detection rate of FRα in patients with clear cell carcinoma and endometrioid carcinoma is less than 50%, these two pathological types of advanced ovarian cancer patients are also uncommon, less than 25%.

[0037] Finally, in patients with several other rare types of advanced ovarian cancer, the detection rate of FRα was only 20%, but in 106 patients, the detection rate of FRα reached 73.58% (TPS≥25%) and 90.57% (TPS≥1%).

[0038] In summary, the folate receptor α detection kit of the present invention explores the optimal immunohistochemical staining process for ovarian cancer tissue section samples. Compared with other staining kits of the same type, it has higher positive intensity and lower staining background. More importantly, the kit of the present invention can assist clinicians in screening ovarian cancer patients who can be treated with ADC drugs targeting FRα, avoid ineffective treatment for patients with FRα-negative expression, increase the medication options for FRα-positive ovarian cancer patients, provide clinicians with more individualized treatment plans, and improve the quality of life of ovarian cancer patients. Finally, the kit of the present invention is also equipped with negative and positive quality control cells to monitor whether the reagent quality from the sample detection process is qualified and whether the detection operation is accurate, to ensure the credibility of the staining results.

[0039] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the above embodiments do not limit the present invention in any form, and any technical solution obtained by equivalent replacement or equivalent transformation falls within the protection scope of the present invention.

Claims

1. A folate receptor alpha detection kit for companion diagnosis of ovarian cancer patients, characterized in that: The method comprises: a negative quality control product and a positive quality control product, wherein the negative quality control product is a paraformaldehyde solution containing FRα-negative cells, and the positive quality control product is a paraformaldehyde solution containing FRα-positive cells. The FRα-negative cells are human embryonic kidney cells HEK293, and the FRα-positive cells are human cervical cancer cells Hela.

2. A folate receptor alpha detection kit for companion diagnosis of ovarian cancer patients according to claim 1, characterized in that: The concentration of HEK293 cells in the negative control and the concentration of Hela cells in the positive control were both 1×10 4 Pieces / mL.

3. A folate receptor alpha detection kit for companion diagnosis of ovarian cancer patients according to claim 1, characterized in that: The paraformaldehyde solution comprises the following components in percentage by weight: 3% to 5% paraformaldehyde, 0.1% to 0.5% pH stabilizer, and the balance is water.

4. A folate receptor alpha detection kit for companion diagnosis of ovarian cancer patients according to claim 3, characterized in that: The pH stabilizer includes disodium hydrogen phosphate and potassium dihydrogen phosphate in a mass ratio of 5-10:

1.

5. A folate receptor alpha detection kit for companion diagnosis of ovarian cancer patients according to claim 1, characterized in that: The method of using the kit is as follows: S1. Sample preparation: Cryosection the neutral formalin-fixed and paraffin-embedded ovarian cancer tissue samples, fix them on glass slides, drop negative and positive quality control samples near the ovarian cancer tissue sections, and place the samples in an oven to dry; S2. Sample testing: Use the detection kit to perform immunohistochemical staining on the prepared samples above and observe the staining results.

6. A folate receptor alpha detection kit for companion diagnosis of ovarian cancer patients according to claim 3, characterized in that: In the step S1, the thickness of the ovarian cancer tissue sample slice is 4-5 μm, and the amount of the negative quality control cells and the positive quality control cells are both 5-10 μL.

7. A folate receptor alpha detection kit for companion diagnosis of ovarian cancer patients according to claim 3, characterized in that: When the negative quality control cell HEK293 staining result is negative, and the positive quality control cell Hela staining result is positive, the staining result of the ovarian cancer tissue section sample is interpreted as follows: (1) When tumor cells show incomplete membrane positive staining or no positive staining, the staining intensity is 0; (2) When tumor cells show incomplete membrane-positive staining and can only be observed under a 40x microscope, the staining intensity is 1+; (3) When the tumor cells show partially intact membrane positive staining and can be observed under a 10x microscope, the staining intensity is 2+; (4) When tumor cells show complete membrane positive staining and can be observed under a 4x microscope, the staining intensity is 3+.

8. A folate receptor alpha detection kit for companion diagnosis of ovarian cancer patients according to claim 5, characterized in that: The ratio of tumor cells with staining intensity of 2+ and 3+ to all live tumor cells with staining intensity of 0, 1+, 2+, and 3+ was calculated according to the following formula, namely, the Tumor Proportion Score (TPS):

9. A folate receptor alpha detection kit for companion diagnosis of ovarian cancer patients according to claim 6, characterized in that: The interpretation criteria for sample staining results are: (1) If TPS is less than 50%, it is interpreted as negative, and the ovarian cancer patient is not suitable for ADC drug treatment targeting FRα; (2) If TPS ≥ 75%, it is interpreted as positive, and the ovarian cancer patient can benefit significantly from ADC drug treatment targeting FRα; (3) If 50%≤TPS<75%, it is not recommended for the ovarian cancer patient to receive ADC drug treatment targeting FRα.

10. Use of the detection kit according to any one of claims 1 to 9, characterized in that: Used to assist clinicians in screening ovarian cancer patients who can be treated with ADC drugs targeting FRα.

Citation Information

Patent Citations

  • Method for cancer prognosis using cellular folate vitamin receptor quantification

    CN101203759A

  • Detection kit for ovarian cancer cell folate receptor alpha and application thereof

    CN117741149A

  • Antibody recognizing folate receptors alpha and beta

    US20150343088A1